PBX1 is a valuable prognostic biomarker for patients with breast cancer

Ao, Xiang; Ding, Wei; Hu, Ge; Zhang, Yuan; Liu, Ying

doi:10.3892/etm.2020.8705

Cited by 28 publications

(18 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, among several stemness-related genes, the expression of pre-B-cell leukemia transcription factor 1 ( PBX1) was significantly downregulated by DATS treatment in both MCF-7 and MDA-MB-231 cells (data not shown). Overexpression of PBX1 has been reported in the stroma of invasive breast cancer, and ductal and invasive lobular breast cancers when compared to normal mammary tissue [ 27 ]. Moreover, a high PBX1 expression was associated with poor prognosis in ER+ breast cancer patients [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…Overexpression of PBX1 has been reported in the stroma of invasive breast cancer, and ductal and invasive lobular breast cancers when compared to normal mammary tissue [ 27 ]. Moreover, a high PBX1 expression was associated with poor prognosis in ER+ breast cancer patients [ 27 ]. Additional significantly ( P = 0.05 or lower) downregulated genes in DATS-treated MDA-MB-231 cells included ARID1A , CNOT1 , HIF1A , JAG1 , LEO1 , SETD2 , SEMA3C , and ZC3H13 (data not shown).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanistic Targets of Diallyl Trisulfide in Human Breast Cancer Cells Identified by RNA-seq Analysis

et al. 2021

View full text Add to dashboard Cite

Diallyl trisulfide (DATS), a metabolic by-product of processed garlic, is highly effective in inhibiting growth of human breast cancer cells in vitro and in vivo, but the underlying mechanisms are still not fully understood. In this study, we performed RNA-seq analyses using luminal-type (MCF-7) and basal-like (MDA-MB-231) human breast cancer cells to identify mechanistic targets of DATS. The Reactome Pathway Analysis revealed upregulation of genes associated with SLIT/ROBO tumor suppressor signaling following DATS treatment in both MCF-7 and MDA-MB-231 cells. However, the expression of SLIT2 and ROBO1 proteins or their downstream target C-X-C motif chemokine receptor 4 was not affected by DATS treatment in both cell lines. The Reactome as well as the Gene Ontology Pathways Analyses of the RNA-seq data from DATS-treated cells indicated downregulation of genes associated with G 2 /M phase cell cycle arrest in comparison with vehicle-treated control cells. Consistent with the RNA-seq data, DATS treatment caused a significant increase in the fraction of the G 2 /M population in both cell lines when compared to corresponding control cells. In addition, Ser10 phosphorylation of histone H3, a mitotic marker, was also increased significantly following DATS treatment in MCF-7 and MDA-MB-231 cells. These results indicate that while SLIT/ROBO signaling is not affected by DATS treatment, cell cycle arrest likely contributes to the antitumor effect of this phytochemical.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mechanistic Targets of Diallyl Trisulfide in Human Breast Cancer Cells Identified by RNA-seq Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore, we need valuable novel biomarkers as prognostic predictors for cancer patients to effectively increase the prognosis and precise therapy effects of cancer patients. Fortunately, some open bioinformatics databases have been established by biomedical researchers, such as Oncomine [36], CCLE [25], cBioPortal [29], and some potential novel biomarkers were identi ed as valuable prognostic predictors and therapeutic targets [37][38][39].…”

Section: Discussionmentioning

confidence: 99%

Systematic Analyses of the Expression, Function, and Prognostic Value of CCNBs in Breast Caner

Liu

Yu-qi

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Cyclin B (CCNB) family plays key roles in the cell cycle, cell division and proliferation. Three members of CCNB family have been identified, including CCNB1, CCNB2 and CCNB3. Many studies have explored the roles of CCNBs in the tumorigenesis and pathogenesis of different types of cancer. However, the expression level, function, and prognostic value of CCNBs in breast caner (BC) are still unclear.Methods We explored the specific alterations of CCNBs in BC and predicted their prognostic value for BC patients. Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier plotter, cBioPortal, STRING, Database for Annotation,Visualization and Integrated Discovery (DAVID) databases were used for above analyses.Results We found that CCNB1 amd CCNB2 were significantly overexpressed in BC compared with normal samples, but not CCNB3. Survival analysis showed that upregulated CCNB1 and CCNB2 expression levels were associated with poor prognosis of BC patients, while high CCNB3 expression was related to good prognosis for BC patients. Furthermore, gene oncology (GO) enrichment analysis was performed to reveal the functions of CCNBs and the interacted genes related to CCNBs. In addition, hsa-miR-139-5p and has-miR-944 were identified to be potentially involved in the regulation of CCNB1.Conclusion Our study suggests that CCNB1, CCNB2 are potential targets of precise therapy for BC patients and that CCNB3 is a novel biomarker for the good prognosis of BC patients.

show abstract

“…Various traditional early detection methods including X-ray, CT, MRI, and ultrasound have been used to diagnose breast cancer [ 55 , 56 ]. In recent years, biomarkers in breast cancer are found and used not only to predict the invasiveness [ 57 ], recurrence, distant metastases, and prognosis [ 58 , 59 ], but also to predict the response to chemotherapy [ 60 ], monitor the use of medicine [ 61 ], and being the target of therapy [ 62 ] to earn time and quality of life for patients. Fortunately, consensus has been reached by biomedical researchers to establish bioinformatics database such as Oncomine [ 63 ], TCGA database [ 64 ], CCLE database [ 65 ], and so on to discover and predict potential biomarkers and therapeutic targets which could be verified by experiments furthermore.…”

Section: Discussionmentioning

confidence: 99%

Identification of ZG16B as a prognostic biomarker in breast cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn’t been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan–Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.

show abstract

PBX1 is a valuable prognostic biomarker for patients with breast cancer

Cited by 28 publications

References 59 publications

Mechanistic Targets of Diallyl Trisulfide in Human Breast Cancer Cells Identified by RNA-seq Analysis

Mechanistic Targets of Diallyl Trisulfide in Human Breast Cancer Cells Identified by RNA-seq Analysis

Systematic Analyses of the Expression, Function, and Prognostic Value of CCNBs in Breast Caner

Identification of ZG16B as a prognostic biomarker in breast cancer

Contact Info

Product

Resources

About